MedTrace Logo

International Registry of Thrombotic APS Patients Treated With Direct Oral Anticoagulants

NCT04262492 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2026-05-08

No results posted yet for this study

Summary

This registry, currently being established will ensure consistency of data collection and provide safety information in non high-risk APS patients currently on DOACs.

Conditions

  • Antiphospholipid Syndrome
  • Thrombosis
  • Anticoagulants Causing Adverse Effects in Therapeutic Use

Interventions

DRUG

Rivaroxaban

Rivaroxaban 10 mg or 15 mg or 20 mg OD Dabigatran 110 mg or 150 mg BID Apixaban 2.5 mg or 5 mg or 10 mg BID

Sponsors & Collaborators

  • International Society on Thrombosis and Haemostasis

    collaborator UNKNOWN

  • Stéphane Zuily

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-21
Primary Completion
2030-04-21
Completion
2031-04-21
FDA Drug
Yes

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04262492 on ClinicalTrials.gov